Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitomycin C-induced renal toxicity, a dose-dependent side effect?

J Verwey1, J de Vries, H M Pinedo

  • 1Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.

European Journal of Cancer & Clinical Oncology
|February 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society·2000
Same author

Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.

The oncologist·2000
Same author

Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.

European journal of cancer (Oxford, England : 1990)·2000
Same author

Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.

Clinical cancer research : an official journal of the American Association for Cancer Research·2000
Same author

Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2000
Same author

Human natural killer T cells acquire a memory-activated phenotype before birth.

Blood·2000
Same journal

The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer.

European journal of cancer & clinical oncology·1989
Same journal

Nutritional factors and cancers of the breast, endometrium and ovary.

European journal of cancer & clinical oncology·1989
Same journal

Reproductive factors and cancers of the breast, ovary and endometrium.

European journal of cancer & clinical oncology·1989
Same journal

Multiple primary cancers of the breast, endometrium and ovary.

European journal of cancer & clinical oncology·1989
Same journal

Cancers of the breast, endometrium and ovary: geographic correlations.

European journal of cancer & clinical oncology·1989
Same journal

Hormone replacement therapy in women treated for breast cancer.

European journal of cancer & clinical oncology·1989
See all related articles

Mitomycin C (MMC) can cause kidney damage. This study suggests MMC-induced nephrotoxicity is dose-dependent, appearing at higher cumulative doses, with an incidence likely below 10%.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Mitomycin C (MMC) has been recognized for its nephrotoxic potential since 1971.
  • Limited data exist regarding the dose-dependency and incidence of MMC-induced nephrotoxicity.
  • This prospective study aimed to clarify these aspects of MMC's renal side effects.

Purpose of the Study:

  • To investigate the dose-dependency of Mitomycin C (MMC)-related renal toxicity.
  • To determine the incidence of nephrotoxicity in patients treated with MMC.
  • To evaluate the utility of laboratory tests in predicting MMC-induced renal side effects.

Main Methods:

  • A prospective study involving 44 patients treated with Mitomycin C (MMC).
  • 37 patients were evaluable for renal function, hemolysis, and coagulation disorders via extensive serial laboratory tests.

Related Experiment Videos

  • Results were analyzed based on cumulative MMC dose levels, supplemented by a literature review.

    • Main Results:

    • One patient experienced a fatal hemolytic uremic syndrome after a cumulative dose of 40 mg/m2 MMC.
    • No other patients exhibited renal toxicity, and all laboratory tests remained within normal limits.
    • Predictive value of standard laboratory tests for MMC-induced nephrotoxicity was not established.

    Conclusions:

    • Mitomycin C (MMC)-related renal toxicity appears to be a dose-dependent side effect.
    • Nephrotoxicity is associated with cumulative doses of 30 mg/m2 or higher.
    • The overall incidence of MMC-induced nephrotoxicity is estimated to be less than 10%.